z-logo
Premium
A bivalent B‐cell epitope dendrimer peptide can confer long‐lasting immunity in swine against foot‐and‐mouth disease
Author(s) -
CañasArranz Rodrigo,
Forner Mar,
Defaus Sira,
RodríguezPulido Miguel,
León Patricia,
Torres Elisa,
Bustos María J.,
Borrego Belén,
Sáiz Margarita,
Blanco Esther,
Andreu David,
Sobrino Francisco
Publication year - 2020
Publication title -
transboundary and emerging diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.392
H-Index - 63
eISSN - 1865-1682
pISSN - 1865-1674
DOI - 10.1111/tbed.13497
Subject(s) - epitope , virology , foot and mouth disease virus , immune system , biology , bivalent (engine) , t cell , antibody , virus , immunity , immunology , chemistry , organic chemistry , metal
Foot‐and‐mouth disease virus (FMDV) causes a widely extended contagious disease of livestock. We have previously reported that a synthetic dendrimeric peptide, termed B 2 T(mal), consisting of two copies of a B‐cell epitope [VP1(140–158)] linked through maleimide groups to a T‐cell epitope [3A(21–35)] of FMDV, elicits potent B‐ and T‐cell‐specific responses and confers solid protection in pigs to type O FMDV challenge. Longer duration of the protective response and the possibility of inducing protection after a single dose are important requirements for an efficient FMD vaccine. Herein, we show that administration of two doses of B 2 T(mal) elicited high levels of specific total IgGs and neutralizing antibodies that lasted 4–5 months after the peptide boost. Additionally, concomitant levels of IFN‐γ‐producing specific T cells were observed. Immunization with two doses of B 2 T(mal) conferred a long‐lasting reduced susceptibility to FMDV infection, up to 136 days (19/20 weeks) post‐boost. Remarkably, a similar duration of the protective response was achieved by a single dose of B 2 T(mal). The effect on the B 2 T(mal) vaccine of RNA transcripts derived from non‐coding regions in the FMDV genome, known to enhance the immune response and protection induced by a conventional inactivated vaccine, was also analysed. The contribution of our results to the development of FMD dendrimeric vaccines is discussed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here